ERBB2 and breast cancer: Many trials of immunotherapy have targeted HER2/neu, with significant impact of HER2-directed monoclonal antibodies (Mab), including trastuzumab, pertuzumab, neratinib, lapatinib, and T-DM1 in HER2-positive breast cancer patients [83].